GlobeNewswire Inc.··Eisai Co., Ltd. And Biogen Inc.FDA Extends Review of Eisai-Biogen's LEQEMBI Subcutaneous Formulation to August 2026
FDA extends LEQEMBI IQLIK subcutaneous review to August 2026 without raising approvability concerns, maintaining regulatory momentum for Eisai and Biogen's reformulated Alzheimer's treatment.
BIIBFDA approvalsubcutaneous injection